| Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. | |
| | |
MedLine Citation:
|
PMID: 20124179 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE To address the impact of positron emission tomography with [(18)F]fluorodeoxyglucose (PET-FDG) on the initial staging and management of patients with head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS This multicenter, prospective study included 233 patients with newly diagnosed and untreated HNSCC. TNM stage and therapeutic decision were first determined based on the conventional work-up (including physical examination, computed tomography [CT]/magnetic resonance imaging of the head and neck region, and thoracic CT) and sealed in envelope 1. Whole-body PET-FDG was then performed, and subsequent TNM stage and therapeutic decision were written in envelope 2. Changes in TNM stages and in patient management as a result of PET-FDG imaging were recorded. Clinical outcome and histopathology were used as gold standards to validate the TNM stage. Conventional and PET stages were compared using the McNemar test. Results Conventional and PET stage were discordant in 100 (43%) of 233 patients. PET proved to be accurate in 47 patients and inaccurate in 13 patients. TNM status was left unconfirmed in 40 patients because no therapeutic change was expected from the stage difference. Conventional + PET TNM classification (envelope 2) was significantly more accurate than conventional classification (envelope 1; P < .0001, McNemar test). PET-FDG altered the therapeutic plan in 32 (13.7%) of 233 patients. CONCLUSION Adding whole-body PET-FDG to the pretherapeutic conventional staging of HNSCC improved the TNM classification of the disease and altered the management of 13.7% of patients. These findings support the implementation of PET-FDG in the routine imaging work-up of HNSCC. |
| | |
Authors:
|
Max Lonneux; Marc Hamoir; Hervé Reychler; Philippe Maingon; Christian Duvillard; Gilles Calais; Boumédiène Bridji; Laurence Digue; Michel Toubeau; Vincent Grégoire |
Related Documents
:
|
11587059 - Positron emission tomography: brain tumors and lung cancer. 9885779 - Imaging of abdominal manifestations of melanoma. 18539889 - Non-small cell lung cancer: whole-body mr examination for m-stage assessment--utility f... 11214619 - Correlations of serum ca125 level and computerized tomography (ct) imaging with laparot... 17180659 - Integrated pet/ct as a first-line re-staging modality in patients with suspected recurr... 11973489 - Reproducibility and clinical value of 18f-fluorodeoxyglucose positron emission tomograp... 20047059 - Insensitivity of visual assessment of hippocampal atrophy in familial alzheimer's disease. 8526229 - The profession's image, 1917-1925, part ii: occupational therapy as represented by the ... 8357619 - Imaging the sphenoid bone and basiocciput: pathological considerations. |
Publication Detail:
|
Type: Journal Article; Multicenter Study Date: 2010-02-01 |
Journal Detail:
|
Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Volume: 28 ISSN: 1527-7755 ISO Abbreviation: J. Clin. Oncol. Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-25 Completed Date: 2010-03-25 Revised Date: 2010-10-05 |
Medline Journal Info:
|
Nlm Unique ID: 8309333 Medline TA: J Clin Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 1190-5 Citation Subset: IM |
Affiliation:
|
Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, Avenue Hippocrate, 10, B-1200 Brussels, Belgium; max.lonneux@uclouvain.be. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Carcinoma, Squamous Cell / pathology, radionuclide imaging, therapy* Female Fluorodeoxyglucose F18 / diagnostic use* Head and Neck Neoplasms / pathology, radionuclide imaging, therapy* Humans Male Middle Aged Neoplasm Staging Positron-Emission Tomography Prospective Studies Radiopharmaceuticals / diagnostic use* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
| Comments/Corrections | |
Comment In:
|
J Clin Oncol. 2010 Oct 1;28(28):e515
[PMID:
20606098
]
J Clin Oncol. 2010 Oct 1;28(28):e516; author reply e517 [PMID: 20606097 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiat...
Next Document: Temporal trends in cause-specific late mortality among 5-year survivors of childhood cancer.